New hope for young cancer patients: experimental combo targets hard-to-treat tumors

This study tests a new drug, PEN-866, combined with two standard chemotherapy drugs (vincristine and temozolomide) for adolescents and young adults aged 12-39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have returned or not responded to standard treatments. The goal is to see if this combination can shrink tumors or stop them from growing. Participants receive the drugs in 21-day cycles for up to 18 cycles, with regular check-ups and questionnaires about their well-being.